Celera Sued Over Plans to Sell to Quest | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The New Orleans Employees Retirement System is suing Celera, alleging its plan to sell the company to Quest Diagnostics for $671 million undervalues the company.

Along with Celera, its CEO, Kathy Ordoñez, and its board of directors are named as defendants in the lawsuit filed in Delaware Chancery Court. Quest and its wholly owned subsidiary, Spark Acquisition, are also named as defendants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.